Oxford's contractor market is anchored by life sciences, biotech and research-driven technology. The science parks, innovation campuses and the major research facilities around the city host pharmaceutical and biotech firms, deep-tech and instrumentation companies, and a strong pipeline of university spinouts in areas such as therapeutics, diagnostics, quantum and space. This generates demand for highly specialised contractors: scientific, clinical and regulatory professionals in pharma and biotech, plus research engineers, data scientists, embedded and systems software developers and technical project managers. Where the end client is a large pharma company or an established technology firm, off-payroll Chapter 10 applies and the client issues the status determination statement.

As in Cambridge, the defining dynamic is the mix of client sizes. Oxford produces a high volume of early-stage spinouts and scale-ups, many of which genuinely meet the small-company tests (two of £15m turnover, £7.5m balance sheet and 50 employees). A small end client keeps the status decision with the contractor under Chapter 8, where the PSC self-assesses and the 5% expenses allowance survives, and even a fast-growing spinout that crosses the thresholds is not obliged into Chapter 10 until 6 April 2027 at the earliest because of the two-consecutive-years rule and the relevant-financial-year lag. So an Oxford contractor can be inside-determined by a large pharma client and outside (self-assessed) for a small spinout in the same year.

The technical and scientific character of Oxford contracting cuts both ways on status. Genuine specialist expertise, autonomy over method and engagement for a defined deliverable point toward outside IR35 and being in business on your own account, but long embedded engagements in a large client's research or clinical function raise the standard control and mutuality questions. We map each client to the correct regime, review contracts and working practices before you sign, check status determination statements for large clients, support the 45-day client-led disagreement process where an inside finding looks wrong, and model umbrella versus limited company honestly, flagging the April 2026 umbrella joint-and-several-liability change.